

## LifeNet Health LifeSciences will showcase innovative all-human research solutions at SOT ToxExpo

- Featuring pre-clinical research solutions to include an all-human triculture model, thyrocytes for use in 3D models, and genotyped human hepatocytes
- A series of engaging events during SOT will offer researchers opportunities to connect directly with LifeNet Health LifeSciences subject matter experts

**Virginia Beach, Va.** (March 21, 2022) – LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, will showcase a unique new triculture system during the Society of Toxicology Annual Meeting and ToxExpo in San Diego, March 27-31. The triculture system is the first all-human liver model to offer unparalleled human relevance, along with a new level of reproducibility and predictability.

LifeNet Health LifeSciences will also offer a live exhibitor-hosted session and four poster presentations at SOT – in addition to showcasing a full portfolio of human-based cell, biospecimen, and cell-model solutions, including primary human hepatocytes and liver non-parenchymal cells; snap frozen and FFPE block liver tissue samples; healthy and diseased tissues for comparative studies; and a prospective research biospecimen program.

“Increasingly, use of human cells and tissues is a must-have during every stage of the drug discovery pipeline,” said Louis Dias, General Manager of LifeNet Health LifeSciences. “Our unique innovations bring new levels of precision and consistency to *in vitro* biology, to accelerate development of safer, more effective treatments.”

SOT attendees can learn more by visiting the LifeNet Health LifeSciences subject matter experts at booth #2204. Additional activities during the meeting include:

- Chief Scientist Ed LeCluyse, PhD, will offer an exhibitor-hosted session on the new LifeNet Health LifeSciences triculture system on March 28 from 9 to 10 a.m. PST.
- Scientist Eda Rogers, PhD, will present a poster titled “An *In Vitro* Human Thyroid Model to Screen and Classify Thyroid-Disrupting Chemicals with Various Modes of Action” on March 28 from 2:30 to 4:15 p.m. PST.
- Mary Jane Cunningham, PhD, Director for Clinical Applications and Services, will present a poster titled “Application of Activity Scoring System to Analyze Trends in Primary Human Hepatocytes’ Donor Genotypes” on March 29 from 9 to 10:45 a.m. PST.
- Scientist Jessica Weaver, PhD, will present a poster titled “Characterization of Morphology, Longevity, and Functionality in an All-Human Cell Based Tri-Culture System” on March 30 from 10:45 a.m. to 12:30 p.m. PST.
- Dr. LeCluyse will present a poster titled “An *In Vitro* Tri-Culture System to Assess Compound-Induced Hepatic Clearance of Thyroxine in Humans,” based on research from Kristina Wolf, PhD, in collaboration with Corteva Agriscience, on March 30 from 10:45 a.m. to 12:30 p.m. PST.

Get the latest SOT news and announcements by visiting [LNHLifeSciences.org/SOT](http://LNHLifeSciences.org/SOT).

### About LifeNet Health LifeSciences

LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider – with a commitment to providing game-changing innovations in human *in vitro* biology. Discover more at [LNHLifeSciences.org](http://LNHLifeSciences.org).

###